Back to search

Article

Repurposing chlorpromazine as add-on in the adjuvant phase of first-line glioblastoma therapeutic protocol in patients carrying hypo-/un-methylated<i>MGMT</i>gene promoter: RACTAC, a Phase II multicenter single-arm clinical trial

2023-02-24

Abstract excerpt

<h4>Background</h4> Glioblastoma (GBM) is a devastating brain tumor with poor prognosis, characterized by rapid growth and invasion into surrounding brain tissue. It is a hard-to-treat cancer and represents an unmet medical need. In recent years, there has been a growing interest in developing novel approaches to improve the outcomes of GBM patients; among these, drug repurposing. Our preclinical studies identifie...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
1e8a782b-35e5-54e1-a604-819cc8c748d1
DOI
10.1101/2023.02.21.23286088
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Repurposing chlorpromazine as add-on in the adjuvant phase of first-line glioblastoma therapeutic protocol in patients carrying hypo-/un-methylated<i>MGMT</i>gene promoter: RACTAC, a Phase II multicenter single-arm clinical trialDOI 10.1101/2023.02.21.23286088
Chlorpromazine Overcomes Temozolomide Resistance in Glioblastoma by inhibiting Cx43 and Essential DNA Repair PathwaysSemantic proximity
Multifaceted effect of chlorpromazine in cancer: implications for cancer treatmentSemantic proximity
Chlorpromazine Induces Cytotoxic Autophagy in Glioblastoma Cells via Endoplasmic Reticulum Stress and Unfolded Protein ResponseSemantic proximity
Chlorpromazine overcomes temozolomide resistance in glioblastoma by inhibiting Cx43 and essential DNA repair pathwaysSemantic proximity
MGMT in TMZ-based glioma therapy: Multifaceted insights and clinical trial perspectivesSemantic proximity
Combination of Imipridone ONC201 or ONC206 with Temozolomide and Radiotherapy in triple ITR therapy reduces intracranial tumor burden and prolongs survival in an orthotopic wild-type IDH GBM mouse modelSemantic proximity
Circadian regulation of <i>MGMT</i> expression and promoter methylation underlies daily rhythms in TMZ sensitivity in glioblastomaSemantic proximity
<i>MGMT</i> METHYLATION IS A PROGNOSTIC BIOMARKER IN ELDERLY PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMASemantic proximity
Novel Imidazotetrazine Evades Known Resistance Mechanisms and Is Effective against Temozolomide-Resistant Brain Cancer in Cell CultureSemantic proximity
Identification of thioridazine, an antipsychotic drug, as an antiglioblastoma and anticancer stem cell agent using public gene expression dataSemantic proximity
Inhibition of DNA-repair genes Ercc1 and Mgmt enhances temozolomide efficacy in gliomas treatment: a pre-clinical studySemantic proximity
Proton pump inhibitors are detrimental to overall survival of patients with glioblastoma multiforme: results from a nationwide real-world evidence databaseSemantic proximity
Select a neighboring publication to make it the new centre.